Report – Insights on Quality from FDA Leaders

Areas examined in this report:

• Pharma compliance issue trends
• The role of EIRs
• When FDA inspections are classified as OAI
• Timing of surveillance inspections following pre-approval inspections
• A case study in contamination failures that led to patient deaths
• The series of events that resulted in a company coming under a consent decree